By Gina Shaw
Cigna has reached agreements with both Amgen and Sanofi/Regeneron on value-based contracts for their proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, evolocumab (Repatha) and alirocumab (Praluent), the company recently announced. The contracts modify manufacturer reimbursement for the cholesterol-lowering drugs based on how well patients respond to their medications.
“The contracts are independent of each other, but they share the same overall objective,”